<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">38</article-id><article-id pub-id-type="doi">10.25208/0042-4609-2014-90-3-95-104</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL PRACTICE GUIDELINES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Particular features of the clinical course of the papilloma viral infection depending on quantitative indices of human papilloma viruses of a high carcinogenic risk</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности клинического течения папилломавирусной инфекции в зависимости от количественных показателей вирусов папилломы человека высокого онкогенного риска</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rakhmatulina</surname><given-names>M. R.</given-names></name><name xml:lang="ru"><surname>Рахматулина</surname><given-names>М. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>sanabol@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bolshenko</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Большенко</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>sanabol@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kuevda</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Куевда</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>sanabol@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Trofimova</surname><given-names>O. B.</given-names></name><name xml:lang="ru"><surname>Трофимова</surname><given-names>О. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>sanabol@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">State Research Center of Dermatovenereology and Cosmetology, Ministry of healthcare of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Russian Medical Academy of Postgraduate Studies, Ministry of Health Russian Federation</institution></aff><aff><institution xml:lang="ru">ГБОУ ДПО «Российская медицинская академия последипломного образования» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Central Research Institute of Epidemiology, Russian Inspectorate for Protection of Consumer Right and Human Welfare</institution></aff><aff><institution xml:lang="ru">ФБУН «Центральный научно-исследовательский институт эпидемиологии» Роспотребнадзора</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2014-06-24" publication-format="electronic"><day>24</day><month>06</month><year>2014</year></pub-date><volume>90</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>95</fpage><lpage>104</lpage><history><date date-type="received" iso-8601-date="2017-08-24"><day>24</day><month>08</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Rakhmatulina M.R., Bolshenko N.V., Kuevda D.A., Trofimova O.B.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, Рахматулина М.Р., Большенко Н.В., Куевда Д.А., Трофимова О.Б.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Rakhmatulina M.R., Bolshenko N.V., Kuevda D.A., Trofimova O.B.</copyright-holder><copyright-holder xml:lang="ru">Рахматулина М.Р., Большенко Н.В., Куевда Д.А., Трофимова О.Б.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/38">https://vestnikdv.ru/jour/article/view/38</self-uri><abstract xml:lang="en"><p>Goal of the study. To study the dependence of the clinical course of the papilloma viral infection and cytological characteristics of lesions in the cervical mucosa on the quantitative indices of human papilloma virus (HPV). Materials and methods. The study involved 175 female patients with HPV of a high carcinogenic risk including 125 subjects with clinical forms of the papilloma viral infection (PVI) and 50 subjects with subclinical and latent forms of the disease. Laboratory tests were carried out with the use of the polymerase chain reaction including real-time PCR for the quantitative determination of HPV. Cytological examinations of scrapes from the exocervical and endocervical mucosa were carried out according to Leishman I, and the results were interpreted according to Bethesda. Results. The authors established an association between clinical forms of PVI and infection with two or more HPV genotypes, and latent and subclinical forms of the disease and infection with one HPV genotype; HPV Genotype 16 prevails within the structure of HPV of a high carcinogenic risk. It was shown that patients infected with two or more HPV genotypes as well as subjects with subclinical and latent forms of the disease underwent reliably higher viral loads than subjects with anogenital warts and patients infected with one HPV genotype only. A higher HPV viral load was also noted in case of a persisting course of PVI and in patients with high-grade squamous intraepithelial lesions (H-SIL). Conclusion. Women with latent and subclinical forms, persistent PVI course and infected with two or more HPV genotypes of a high carcinogenic risk belong to the high-risk group developing expressed epithelial affections in the cervical mucosa. Quantitative HPV indices exceeding 5 lg of copies of HPV DNA per 100,000 cells belong to unfavorable predictors for the development of intraepithelial affections in the cervical mucosa and stipulate the need to conduct an additional examination (colposcopy or cytology) to exclude their development.</p></abstract><trans-abstract xml:lang="ru"><p>Цель исследования. Изучение зависимости клинического течения папилломавирусной инфекции (ПВИ) и цитологических особенностей поражения слизистой оболочки шейки матки от количественных показателей вирусов папилломы человека (ВПЧ). Материал и методы. В исследование включены 175 пациенток женского пола, инфицированных ВПЧ высокого онкогенного риска: 125 женщин с клиническими формами ПВИ и 50 женщин с субклиническими и латентными формами заболевания. Лабораторные исследования проводились методом полимеразной цепной реакции, в том числе в режиме реального времени, для количественного определения ВПЧ. Цитологическое исследование соскобов со слизистой оболочки экзоцервикса и эндоцервикса проводилось по Лейшман I с интерпретацией по системе Bethesda. Результаты. Установлена ассоциация клинических форм ПВИ с инфицированием двумя и более генотипами ВПЧ, латентных и субклинических форм заболевания - с инфицированием одним генотипом ВПЧ, при этом преобладающим в структуре ВПЧ высокого онкогенного риска являлся ВПЧ генотипа 16. Показано, что у пациенток, инфицированных двумя и более генотипами ВПЧ, а также с субклиническими и латентными формами заболевания показатели вирусной нагрузки достоверно выше, чем у больных аногенитальными бородавками и инфицированных одним генотипом ВПЧ. Более высокие показатели вирусной нагрузки ВПЧ также регистрировались при персистирующем течении ПВИ и у пациенток с выраженными интраэпителиальными поражениями шейки матки (H-SIL). Заключение. В группе риска развития выраженных эпителиальных поражений слизистой оболочки шейки матки находятся женщины с латентными и субклиническими формами, персистирующим течением ПВИ, инфицированные двумя и более генотипами ВПЧ высокого онкогенного риска. Количественные показатели ВПЧ более 5 lg копий ДНК ВПЧ на 100 тыс. клеток являются неблагоприятным прогностическим фактором развития интраэпителиальных поражений слизистой оболочки шейки матки и обусловливают необходимость проведения дополнительного обследования (кольпоскопического, цитологического) с целью исключения их возникновения.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>генотипирование</kwd><kwd>количественное определение вирусов папилломы человека высокого онкогенного риска</kwd><kwd>папилломавирусная инфекция</kwd><kwd>цитологическое исследование</kwd><kwd>онкологическая патология</kwd><kwd>genotyping</kwd><kwd>quantitative determination of the human papilloma virus of a high carcinogenic risk</kwd><kwd>papilloma viral infection</kwd><kwd>cytologic examination</kwd><kwd>cancer pathology</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Kuznetsova Y.N., Evstigneyeva N.P., Oboskalova T.A. Complex therapy of clinical manifestations of urogenital papilloma-virus infection. Modern probl of dermatovenereol, immunol and med cosmetol 2009; 3 (6): 27-31</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Soloviyov A.M. Immunotherapy with isoprinosine as an adjuvant or independent method of treatment for patients with papilloma viral infection. Vestn dermatol i venerol 2011; 5: 146-151.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Rahmatulina M.R. Experience of the combined therapy of anogenital (veneral) warts. Vestn dermatol i venerol 2012; 4: 105-110.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Kaprin A.D. Zlokachestvennye novoobrazovaniya v Rossii v 2012 godu (zabolevaemost' i smertnost') / Pod redaktsiey A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoy. M: FGBU «MNIOI im. P.A. Gertsena» Minzdrava Rossii, 2014.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Mayrand M-H., Duarte-Franco E., Rodrigues I. et al. Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. New England Journal of Medicine 2007; 357: 1579-1588.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Solomon D., Nayar R. The Bethesda System for reporting cervical cytology. Definition, criteria, and explanatory notes. Springer 2004; XXIII: 191.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Minkina G.N., Shabalova I.P. Klassifikatsiya patologicheskikh izmeneniy sheyki matki. Morfologicheskaya terminologiya. Profilaktika raka sheyki matki. Rukovodstvo dlya vrachey pod redaktsiey G.T. Sukhikh. M: 2012. 38-45.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kitchener H.C., Peto J., Wheeler P. et al. ARTISTIC: a randomized train of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009 Nov; 13 (51): 1-150.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ronco G., Biggeri A., Confortini M. et al. Health technology assessment report: HPV DNA based primary screening for cervical cancer. Epidemiol Prev 2012 May-Aug; 36 (3-4 Suppl): e1-72.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Ronco G., Dillner J., Elfsröm K.M. et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four Europeen randomized controlled trials. The Lancet 2014 February; 383: 9916: 524-532.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Pileggi C., Flotta D., Bianco A., et al. Is HPV DNA testing specificity comparable to that of cytological testing in primary cervical cancer screening? Results of a meta - analysis of randomized controlled trials. HYPERLINK "http:// www.ncbi.nlm.nih.gov/pubmed/?term=Is+HPv+ DNA+testing+specificity+comparable+to+that+o f+cytological+testing+in+primary+cervical+can cer+screening%3F+Results+of+a+meta+%E2% 80%93+analysis+of+randomized+controlled+tri als" \o "International journal of cancer. Journal international du cancer." Int J Cancer 2014 Jul 1; 135 (1): 166-77.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kim J.J., Wright T.C., Goldie S.J. Cost - effectiveness of alternative triage studies for atypical squamous cells of undetermined significance. JAMA 2002; Vol. 287: 2382-2390.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kim J.J., Wright T.C., Goldie S.J. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, the Netherlands, France and Italy. Journal of the National Cancer Institute 2005; 97 (12): 888-895.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Shipulina O.Yu. Algoritm diagnostiki virusa papillomy cheloveka. Spravochnik zaveduyushchego KDL 2010; 1: 3-11.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>World Health Organization (WHO). Comprehensive cervical cancer control: a guide to essential practice. Geneva, 2010</mixed-citation></ref></ref-list></back></article>
